FindMyKOL

Kennedy Ukadike, MD

Enriched profile

Renown Health

ORCID↗NPI↗
✓ Itemized profile
Region🇺🇸 Reno, NV · West · United StatesSpecialtyRheumatologyFocusSystemic Lupus Erythematosus Research+4
Last active 2024FindMyKOL type: RegionalLatest publication2021Online presenceNone verifiedPayments2022–2024NIH fundingNone on fileWhy? →

Kennedy Ukadike is a Systemic Lupus Erythematosus Research physician affiliated with Renown Health. OpenAlex indexes 20 publications with 250 citations (h-index 9).

Data verified 27 Oct 2026

Overview

Updated 28 Oct 2026

Kennedy C. Ukadike, M.D., is affiliated with Renown Health (Renown Rheumatology, Reno, NV). The public record shows 20 publications with 250 citations (h-index 9), centered on Systemic Lupus Erythematosus Research, Vasculitis and related conditions, Systemic Sclerosis and Related Diseases. It also documents industry payments reported by 8 companies.

  • Most recent indexed publication: 2021 · Journal of clinical medicine
  • Top research focus: Systemic Lupus Erythematosus Research
  • Open Payments reporting from 8 companies

Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lupus (SLE)

Research focus

OpenAlex concept fingerprint
Systemic Lupus Erythematosus ResearchVasculitis and related conditionsSystemic Sclerosis and Related DiseasesChromosomal and Genetic VariationsGenomics and Chromatin Dynamics

Drugs & molecules

across trials, industry payments and publications
Benlystageneric · BelimumabClinical trials—Industry payments9Publications—Saphnelogeneric · AnifrolumabClinical trials—Industry payments2Publications—Tremfyageneric · GuselkumabClinical trials—Industry payments2Publications—Enbrelgeneric · EtanerceptClinical trials—Industry payments1Publications—Lupkynisgeneric · VoclosporinClinical trials—Industry payments1Publications—Nucalageneric · MepolizumabClinical trials—Industry payments1Publications—Ofevgeneric · NintedanibClinical trials—Industry payments1Publications—Otezlageneric · ApremilastClinical trials—Industry payments1Publications—Rinvoqgeneric · UpadacitinibClinical trials—Industry payments1Publications—SIMPONI ARIAClinical trials—Industry payments1Publications—Taltzgeneric · IxekizumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
GlaxoSmithKline, LLC.Clinical trials—Industry payments10AstraZeneca Pharmaceuticals LPClinical trials—Industry payments2Janssen Biotech, Inc.Clinical trials—Industry payments2AbbVie Inc.Clinical trials—Industry payments1Amgen Inc.Clinical trials—Industry payments1Aurinia Pharma U.S., Inc.Clinical trials—Industry payments1Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1Lilly USA, LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
20publications

Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.

250citations

Total citations across indexed works.

9h-index

Hirsch index (OpenAlex). i10-index 9.

Clinical & industry

trials, payments and federal funding
0clinical trials

Investigator role on registered studies.

View trials ↓
8companies · 2022–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →

Industry payments

Updated 28 Oct 2026

8 companies reported payments to CMS in program years 2022–2024. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    48.3%
    Folate Analog Metabolic Inhibitor13.9%
    Methotrexate100%
    Part D≥37 patients
    Antirheumatic Agent9.7%
    Leflunomide100%
    Part D≥27 patients

    + 6 more classes in this area

  • Antiparasitic

    21.2%
    Antimalarial21.2%
    Hydroxychloroquine Sulfate100%
    Part D≥61 patients
  • Metabolism & gastrointestinal

    16%
    Corticosteroid12.8%
    Prednisone100%
    Part D≥51 patients
    Aminosalicylate3.1%
    Sulfasalazine Dr100%
    Part D≥12 patients
All 6 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 28 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 28 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Tomas Mustelin12Christian Lood7John LaCava6Martin S. Taylor6Xiaoxing Wang6Kathryn Ni5Anders A Bengtsson4Amanda Laine3Anne M. Stevens3Mary M. Eckert3Rayan Najjar3Anand K. Srivastava3Amanda Hefton2Alison M. Bays2Shu Ying Liang2Sanaa Choufani1Beata Stachowiak1Martin Li1Monica Anne Hrynchak1Bhargavi Duvvuri1Michael A. Bowen1Fatemeh Moadab1Anastasia Khadjinova1John B. Vincent1Cecilia Mustelin1Lynn Dukes‐Rimsky1Lauren M. Pachman1Stephen W. Scherer1Jan M. Friedman1Christian R. Marshall1Victoria A. Carter1Robert A. Saul1Shaohui Hu1Tyler W. Hulett1Elizabeth Pewsey1Gregory F. Guzauskas1Virginie S. Vervoort1Shin‐ichi Horike1Alyssa N. Colyer1Fred J. Dill1

Background & recognition

Updated 28 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →renown.org ↗
  • provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →renown.org ↗

Editorial & leadership roles

journal and society appointments
  • Fellow

    American College of Rheumatology (FACR)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →renown.org ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.